Parvovirus B 19 IgM ELISA kit (DEIA-XY16)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum
Species Reactivity
Human
Intended Use
The Parvovirus B19 IgM (Recombinant) Enzyme Immunoassay Kit measures IgM-class antibodies to Parvovirus B19 in serum.
Contents of Kit
1. Microtiter wells, 12 x 8 (break apart) strips
2. Sample Diluent *, 1 vial, 100 mL
3. IgG-RF-Sorbent*, 1 vial, 6.5 mL
4. High Control *, 1 vial, 2.0 mL
5. Low Control *, 1 vial, 2.0 mL
6. Calibrator*, 1 vial, 2.0 mL
7. Enzyme Conjugate *, 1 vial, 20 mL
8. Substrate Solution, 1 vial, 14 mL
9. Stop Solution, 1 vial, 14 mL
10. Wash Solution *, 1 vial, 30 mL (20X concentrated for 600 mL)

* contain non-mercury preservative
Storage
2-8°C

Citations


Have you cited DEIA-XY16 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Clinical Case of Parvovirus B19 Infection in Pregnant Woman with B-Thalassemia in Bulgaria

CLINICAL LABORATORY

Authors: Voleva, S.; Manolov, V; Krumova, St; Marinov, B.; Vasilev, V.; Shishkov, S.; Nikolaeva-Glomb, L.

A pregnant 30-year-old female in the 34th gestational week was admitted at University "Maichin Dom" Hospital prior to childbirth. The patient is diagnosed with beta-thalassemia. During laboratory screening hemoglobin of 98 g/L was established. Blood smear shows mild microcytic hypochromic anemia: RBC 5.15 x 10(12)/L, HGB 98 g/L, MCV 65.8 fL, MCH 19.4 pg, MCHC 295 g/L. Serum iron concentration is 12.9 mu mol/L and ferritin 17.5 mu g/L. For the delivery process cesium was considered. Two days after procedure a rash presented on face, hands and breasts. Although the mother was positive for parvovirus B19 infection, the baby was negative. This was confirmed by serological and molecular investigations. We discovered only the mother's B19V IgG antibodies in the newborn. In connection to the main disease, namely beta-thalassemia, acute virus infection could cause aplastic crisis. After consultation with a hematologist, serum hepcidin concentration (an iron homeostasis regulator) was quantified: 19.4 mu g/L. ELISA test was used to prove B19V IgM antibodies in the mother. PCR analysis shows the presence of B19V DNA. During infection, inflammatory cytokines increase hepcidin secretion, leading to iron deposition into cells.

Long-term monitoring of virus antibody titers in human intravenous immunoglobulin lots derived from donors in Japan

TRANSFUSION

Authors: Onodera, Hiroyuki; Nakagawa, Risa; Nakagawa, Hitoshi; Urayama, Takeru; Haino, Katsuyuki; Yunoki, Mikihiro

BACKGROUND STUDY DESIGN AND METHODS Intravenous immunoglobulin (IVIG) contains immunoglobulin G against various viruses, except those that have been screened, such as human immunodeficiency and hepatitis C viruses. Antivirus titers reflect the serostatus of the blood donor population in the collection region and are of clinical interest. During the past 10 years, measles, mumps, rubella, varicella-zoster, hepatitis A and B, Epstein-Barr, and human respiratory syncytial viruses; human parainfluenza viruses 1, 2, and 3; human herpes simplex viruses 1 and 2; human herpesvirus 6; cytomegalovirus (CMV); human adenoviruses (HAdVs) 1, 2, 3, 7, and 11; human parvovirus B19; and human echovirus 9 and 11 titers in IVIG lots have been measured by a commercial testing facility. A viral neutralizing assay for CMV has been used at our facility. Herein, we summarize the measurements and results of a regression analysis of the trends in virus antibody titers. RESULTS CONCLUSION IVIG lots contained significant titers against all of the above viruses, except for HAdV 7. Three patterns-stable, increasing, and decreasing-were observed, without any drastic changes. Although these trends reflect the seroprevalence in Japan, the titers were not obviously affected by the cycle of epidemics. On the other hand, the prevalence data suggest that titers against hepatitis A virus and other viruses will decrease in the near future, although they are currently stable. Monitoring the titer of IVIG lots and seroprevalence of donor populations is important for anticipating future changes in virus antibody titers of IVIG lots and can provide useful information of clinical interest.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket